1. Should non-invasive diffuse main-duct intraductal papillary mucinous neoplasms be treated with total pancreatectomy?
- Author
-
William H. Burns, Kelly J. Lafaro, Jin He, Richard A. Burkhart, Matthew J. Weiss, John L. Cameron, Christopher L. Wolfgang, James F. Griffin, Joseph R. Habib, Ross M. Beckman, and Alex B. Blair
- Subjects
medicine.medical_specialty ,endocrine system diseases ,Total pancreatectomy ,medicine.medical_treatment ,Pancreatic Intraductal Neoplasms ,Malignancy ,Main duct ,Article ,Pancreatectomy ,Humans ,Medicine ,Retrospective Studies ,Hepatology ,Intraductal papillary mucinous neoplasm ,business.industry ,Gastroenterology ,medicine.disease ,Pancreaticoduodenectomy ,Adenocarcinoma, Mucinous ,Pancreatic Neoplasms ,Partial Pancreatectomy ,medicine.anatomical_structure ,Dysplasia ,Radiology ,business ,Pancreas ,Carcinoma, Pancreatic Ductal ,Dilatation, Pathologic - Abstract
BACKGROUND: Main-duct (MD) intraductal papillary mucinous neoplasm (IPMN) is associated with malignancy risk. There is a lack of consensus on treatment (partial or total pancreatectomy) when the MD is diffusely involved. We sought to characterize the pancreatic remnant fate after partial pancreatectomy for non-invasive diffuse MD-IPMN. METHODS: Consecutive patients with partial pancreatectomy for non-invasive MD-IPMN from 2004 to 2016 were analyzed. Diffuse MD-IPMN was defined by preoperative imaging as dilation of the MD in the head of the pancreas more than 5mm and involving the whole gland. RESULTS: Of 127 patients with resected non-invasive MD-IPMN, 47 (37%) had diffuse MD involvement. Eleven of 47(23%) patients developed imaging evidence of progression or new cystic disease in the pancreatic remnant. Patients with diffuse MD-IPMN were older (73yrs vs 67yrs, p=0.009), more likely to receive a pancreaticoduodenectomy (96% vs 56%, p
- Published
- 2022